Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Thibault Griseri has been awarded a Career Development Fellowship from Arthritis Research UK to explore haematopoietic stem and progenitor cells as novel therapeutic targets in chronic inflammatory arthritis.

Dr Thibault Griseri has been awarded a Career Development Fellowship from Arthritis Research UK for his project on “Haematopoietic stem and progenitor cells as novel therapeutic targets in chronic inflammatory arthritis”.

Around 10 million people in the UK have arthritis and over 500,000 suffer from chronic inflammatory arthritis. There is yet no cure for this highly disabling and painful condition, although there are many available treatments, which help to slow down the condition. Understanding what causes the inflammation and the chronicity of some types of arthritis is key to the development of better treatments. By bringing together the fields of haematopoiesis – the formation of blood cellular components – and immunology, Dr Griseri’s project will look into how haematopoiesis inside and outside the bone marrow is influenced by inflammatory signals and how haematopoietic stem cells and progenitors cells contribute to chronicity of disease in inflammatory arthritis.

Speaking of his award, Dr Griseri says: "I am delighted and grateful to get this award because it will have a great impact in what is known about arthritis and we will be able to further develop our study of the regulation of haematopoiesis in intestinal inflammatory diseases1 to models of chronic inflammation arthritis and explore the possible crosstalk between intestinal and joint inflammation. Establishing this link will bring us closer to more advanced treatments for this condition."

Similar stories

NIHR funding for musculoskeletal and inflammatory disease research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Leducq Foundation grant boosts cardiovascular research

The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.